» Articles » PMID: 38203206

Identification of MicroRNAs Associated with Histological Grade in Early-Stage Invasive Breast Cancer

Abstract

This study aimed to identify microRNAs associated with histological grade using comprehensive microRNA analysis data obtained by next-generation sequencing from early-stage invasive breast cancer. RNA-seq data from normal breast and breast cancer samples were compared to identify candidate microRNAs with differential expression using bioinformatics. A total of 108 microRNAs were significantly differentially expressed in normal breast and breast cancer tissues. Using clinicopathological information and microRNA sequencing data of 430 patients with breast cancer from The Cancer Genome Atlas (TCGA), the differences in candidate microRNAs between low- and high-grade tumors were identified. Comparing the expression of the 108 microRNAs between low- and high-grade cases, 25 and 18 microRNAs were significantly upregulated and downregulated, respectively, in high-grade cases. Clustering analysis of the TCGA cohort using these 43 microRNAs identified two groups strongly predictive of histological grade. miR-3677 is a microRNA upregulated in high-grade breast cancer. The outcome analysis revealed that patients with high miR-3677 expression had significantly worse prognosis than those with low miR-3677 expression. This study shows that microRNAs are associated with histological grade in early-stage invasive breast cancer. These findings contribute to the elucidation of a new mechanism of breast cancer growth regulated by specific microRNAs.

Citing Articles

The combination of focal breast edema and adjacent vessel sign to assess the behavior of mass-type invasive ductal carcinoma.

Hu J, Ke J, Xu S, Pei L, Cao L, Zhou H BMC Med Imaging. 2024; 24(1):332.

PMID: 39639228 PMC: 11622627. DOI: 10.1186/s12880-024-01518-8.


The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer.

Zhang M, Zheng Z, Wang S, Liu R, Zhang M, Guo Z Cancer Drug Resist. 2024; 7:30.

PMID: 39267922 PMC: 11391347. DOI: 10.20517/cdr.2024.62.

References
1.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

2.
de Hoon M, Imoto S, Nolan J, Miyano S . Open source clustering software. Bioinformatics. 2004; 20(9):1453-4. DOI: 10.1093/bioinformatics/bth078. View

3.
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2019; 30(11):1842. PMC: 6927326. DOI: 10.1093/annonc/mdz215. View

4.
. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

5.
van Agthoven T, Sieuwerts A, Meijer-Van Gelder M, Look M, Smid M, Veldscholte J . Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2008; 27(4):542-9. DOI: 10.1200/JCO.2008.17.1462. View